Qiagen will develop IVDs for use on Illumina's clinical sequencers and reported preliminary Q3 revenue growth of 3 percent at a constant exchange rate.
The companies have expanded an existing partnership to allow physicians to order mental health PGx tests from the EHR and receive CME credit for learning about PGx.
The university also is developing a process for measuring phenotype risk scores as it continually adapts to changing technology and research needs.
Seattle-based Adaptive will develop in vitro diagnostic test kits for distribution, which will run on Illumina's NextSeq 550 Dx system.
The Chan Zuckerberg Initiative is leading efforts to build cloud infrastructure, scale the platform, and distribute data from the project.
Startup BioLizard will develop the algorithm to help Novigenix migrate its immuno-transcriptiomic assay for early colorectal cancer detection to a new NGS-based platform.
The Genomics Research and Innovation Network (GRIN) is a federated platform from three major pediatric hospitals to assist in research and treatment of rare diseases.
The partners are preparing to release two updates to Navify Tumor Board that support automatic importation of structured Foundation Medicine test reports.
Researchers focused on using existing computational methods to fill in gaps in the human microbiome without reference genomes.
23andMe has a holiday popup shop at a mall and could open additional stores, Bloomberg reports.
By studying koalas and a retrovirus that infects them, researchers may have uncovered a new sort of 'immune response' that occurs at the genomic level, Agence France Presse reports.
NPR reports that the first person in the US given a gene editing-based therapy for a genetic disorder is heading home.
In Science this week: ancient genomes reveal social inequality within individual households, new method for quantifying genetic variation in gene dosage, and more.